ALPS A.I CyberSecurity Scoring
28/01/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Alfa Laval - Pharmaceutical Solutions in 2026.
No incidents recorded for Alfa Laval - Pharmaceutical Solutions in 2026.
No incidents recorded for Alfa Laval - Pharmaceutical Solutions in 2026.
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
Latest updates, reports, and threat intel affecting the global network.
Alfa Laval has launched Clariot, an artificial intelligence (AI)-driven solution that monitors the condition of hygienic process equipment.
Alfa Laval introduces Clariot™, an AI-based condition monitoring solution designed for hygienic process equipment, providing precise...
Zephyr's HTTP server (subsys/net/lib/http) provides a static-filesystem resource type (HTTP_RESOURCE_TYPE_STATIC_FS, available when CONFIG_FILE_SYSTEM is enabled) that serves files from a configured root directory. Before this fix, both the HTTP/1 and HTTP/2 front-ends placed the raw, attacker-controlled request path into client-url_buffer (assembled in on_url() for HTTP/1 and copied verbatim from the :path pseudo-header for HTTP/2) without resolving ./.. segments. The static-FS handler then built the on-disk filename by directly concatenating the configured root with that raw URL (snprintk(fname, ..., "%s%s", static_fs_detail-fs_path, client-url_buffer) at http_server_http1.c:603 and http_server_http2.c:490) and opened it with fs_open(fname, FS_O_READ). Because the handler is reached via wildcard/leading-dir (fnmatch FNM_LEADING_DIR) or fallback resource matching, a request such as GET /<prefix/../../<file is dispatched to the handler and, after the underlying filesystem (e.g. LittleFS/FAT) resolves the .. segments, escapes the configured web root, letting an unauthenticated remote client read arbitrary readable files on the mounted volume (information disclosure). The HTTP server requires no TLS or authentication to reach this path. The fix adds http_server_remove_dot_segments(), which canonicalizes the path portion of the URL before resource lookup in both protocol handlers, neutralizing the traversal. Affects releases v4.0.0 through v4.4.0 for deployments that register a static-filesystem resource.
The IPv6 Neighbor Discovery handlers in subsys/net/ip/ipv6_nbr.c (handle_ra_input, handle_ns_input, handle_na_input) used an incorrect boolean expression that combined the RFC 4861 validity checks with the ICMPv6 code check using the wrong operator precedence: the form was '((length/hop/source/target checks) && (icmp_hdr-code != 0))'. Because every legitimate ND message carries ICMPv6 code 0, an attacker setting code == 0 (the normal value) caused the entire predicate to evaluate false, so the packet was never dropped and all of the other checks were silently skipped. The bypassed checks include the mandatory Hop Limit == 255 verification (which proves an ND packet originated on-link and was not forwarded) and, for Router Advertisements, the requirement that the source be a link-local address, as well as multicast-target sanity checks. As a result, an adjacent on-link attacker — and, because the Hop-Limit-255 guard is bypassed, potentially a remote/off-link attacker whose packets would otherwise be rejected — can have forged Router Advertisement, Neighbor Solicitation, and Neighbor Advertisement messages accepted. A forged RA lets the attacker reconfigure the victim's default router, on-link prefixes (SLAAC), MTU, reachable/retransmit timers, and (with CONFIG_NET_IPV6_RA_RDNSS) DNS servers, while forged NS/NA enable neighbor-cache poisoning, enabling man-in-the-middle, traffic redirection, and denial of service. The flaw is an input-validation/authentication weakness rather than a memory-safety issue: the underlying packet-parsing primitives (net_pkt_get_data, net_pkt_read, net_pkt_skip) are independently bounds-safe and the validated 'length' is the true buffer length, so skipping the length check causes no out-of-bounds access. The defect has existed since the logic was introduced in 2018 and shipped in all releases through v4.4.0; it is fixed by splitting the condition so any failing check drops the packet.
A heap buffer overflow in the HighPriorityASDUQueue_hasUnconfirmedIMessages function of lib60870 v2.3.3 to v2.3.6 allows attackers to cause a Denial of Service (DoS) via a crafted payload.
A heap buffer overflow in the TS7Worker::PerformFunctionWrite() function (/core/s7_server.cpp) of snap7 v1.4.3 allows attackers to cause a Denial of Service (DoS) via a crafted packet.
mcumgr_serial_process_frag() in subsys/mgmt/mcumgr/transport/src/serial_util.c calls net_buf_reset() on the result of smp_packet_alloc() before checking it for NULL. smp_packet_alloc() uses net_buf_alloc(K_NO_WAIT) against the shared MCUmgr packet pool (CONFIG_MCUMGR_TRANSPORT_NETBUF_COUNT, default 4), which returns NULL when the pool is exhausted. In default builds the __ASSERT_NO_MSG in net_buf_reset is a no-op, so net_buf_simple_reset writes through the NULL pointer (buf->len = 0; buf->data = buf->__buf), causing a fault/crash. The fragment data reaches this code from attacker-controlled bytes on the MCUmgr serial/UART/shell-console transports (smp_uart.c, smp_raw_uart.c, smp_shell.c), and a fresh buffer is allocated at the start of essentially every new packet. An attacker on the serial/console link can flood the transport to drive the 4-entry buffer pool to exhaustion and induce the NULL dereference, crashing the device (denial of service). The defect was introduced after the original MCUmgr rework and shipped in Zephyr v4.4.0. The fix moves the NULL check ahead of net_buf_reset.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.